Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) PT at $12.89

Key Points

• Compass Therapeutics, Inc. has received an average recommendation of "Buy" from ten analysts, with a 12-month price target of approximately $12.89 per share.
• Several brokers, including Raymond James and Guggenheim, have recently issued positive reports, with price targets ranging from $9.00 to $32.00.
• 68.43% of Compass Therapeutics' stock is currently owned by institutional investors, indicating strong institutional interest in the company.

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have earned a consensus recommendation of "Buy" from the ten analysts that are currently covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $12.8889.

A number of equities research analysts have recently issued reports on the stock. Raymond James Financial raised shares of Compass Therapeutics to an "outperform" rating and set a $9.00 price target on the stock in a report on Tuesday, July 1st. D. Boral Capital reaffirmed a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a research note on Tuesday, August 12th. Finally, Guggenheim raised their target price on shares of Compass Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Tuesday, August 12th.

Institutional Investors Weigh In On Compass Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its stake in Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after purchasing an additional 12,917 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in Compass Therapeutics in the fourth quarter valued at approximately $27,000. Mariner LLC purchased a new stake in Compass Therapeutics in the fourth quarter valued at approximately $30,000. Creative Planning bought a new position in Compass Therapeutics during the second quarter valued at approximately $30,000. Finally, Strs Ohio bought a new position in Compass Therapeutics during the first quarter valued at approximately $34,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock remained flat at $3.37 on Friday. 393,945 shares of the stock were exchanged, compared to its average volume of 1,394,402. Compass Therapeutics has a 52-week low of $1.27 and a 52-week high of $4.08. The stock has a market capitalization of $466.00 million, a P/E ratio of -7.49 and a beta of 1.50. The stock's 50-day moving average price is $3.00 and its 200 day moving average price is $2.48.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). On average, research analysts forecast that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.